ARA-290 vs FOXO4-DRI | Research Comparison | QSC Peptides
ARA-290 vs FOXO4-DRI: Research Comparison
Mechanism, research applications, and key differences
Quick Comparison
Factor
ARA-290
FOXO4-DRI
Primary Target
Innate Repair Receptor (IRR)
See FOXO4-DRI hub
Origin
EPO helix B surface peptide
Distinct origin
Key Research
Phase 2: small fibre neuropathy, metabolic repair
See FOXO4-DRI hub
Detailed Comparison
FOXO4-DRI is a senolytic targeting p21-positive senescent cells; ARA-290 is a cytoprotective peptide that prevents cell death via IRR activation. Opposing mechanisms: FOXO4-DRI clears damaged cells, ARA-290 protects healthy cells from damage.
Which to Choose for Your Research?
The choice depends on your primary research target. ARA-290 is the right tool when the research question involves IRR-mediated cytoprotection — neuropathy models, sarcoidosis inflammation, or metabolic beta cell protection. FOXO4-DRI suits different primary targets. For comprehensive cytoprotection research, some protocols combine both compounds targeting complementary pathways.
